Skip to main content
Delfa

← All assets

Cilostazol

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

0

Recruiting

0

Completed

4

Sites

7

Countries

4

Endpoints

42

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 42 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
2
Phase 4
2
Not applicable
1

Trials by status

Completed
4
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
16
Safety / tolerability / PK
12
Other (unclassified)
8
Neuroimaging
5
Function / daily living
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 13 of 42 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

5

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

3

ADAS-CogCognition

3

ADCS-Activities of Daily Living (ADCS-ADL)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
CAVADCilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Aspirin, Cilostazol

Vascular cognitive impairment / dementia, Mixed / unspecified dementia

Vascular or mixed dementiaPh 4Completed2May 20111
Prevent-SVDLacunar Intervention Trial 1 (LACI-1)

Cilostazol, isosorbide mononitrate

Mixed / unspecified dementia

Age ≥35Ph 2Completed2Aug 20171
NCT02491268A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Cilostazol

MCI / preclinical Alzheimer’s

Mild cognitive impairmentPh 2Completed1Aug 20201
NCT01872858Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

Aspirin, Cilostazol

Vascular cognitive impairment / dementia

Age 50-80Not applicableUnknown1Nov 2012-
NCT01409564Cilostazol Augmentation Study in Dementia

Cilostazol

Alzheimer’s disease

Alzheimer's diseasePh 4Completed1Jun 20121results

Showing 1-5 of 5 trials